Trials / Recruiting
RecruitingNCT05342493
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
AJOVY Subcutaneous Injection Long-term Specified Use-results Survey
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution | The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks. |
Timeline
- Start date
- 2022-04-20
- Primary completion
- 2026-09-30
- Completion
- 2029-06-22
- First posted
- 2022-04-22
- Last updated
- 2025-03-21
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05342493. Inclusion in this directory is not an endorsement.